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Glutathione (GSH) is present in almost
all cell types playing an important func-
tion in organisms. It is the main antiox-
idant in many cell types and it also reg-
ulates the function of proteins, including
transcription factors (reviewed in Pallardó
et al., 2009; Markovic et al., 2010; García-
Giménez et al., 2013a).
Over recent years, growing evidence has
suggested a link between GSH metabolism
and the control of epigenetic mecha-
nisms. Epigenetics is defined as the mitoti-
cally/meiotically heritable changes in gene
expression that are not due to changes
in the primary DNA sequence. This link
between GSH and epigenetics occurs at
different levels. Hence, GSH can affect
DNA and histone methylation, and also
it binds to histones throughout the cys-
teines in the histone H3. Pioneer work
showed how oxidized GSH inhibits the
activity of S-adenosyl methionine syn-
thetase, MAT1A. This key enzyme is
involved in the synthesis of S-adenosyl
methionine (SAM), which is used by DNA
methyltransferases (DNMTs) and histone
methyltransferases (HMTs) as a substrate
for DNA and histone methylation, respec-
tively (Pajares et al., 1992; Martinez-
Chantar and Pajares, 1996). Therefore, it
is possible to alter the methylation sta-
tus of the genome and modify the epi-
genetic signature in cells by modulating
SAM levels. Methylation of DNA and his-
tone constitutes one of the most studied
chemical modifications in the epigenetic
code, which shapes gene-expression pat-
terns usually, but not always, repressing
gene transcription. Interestingly, replen-
ishment of GSH levels recovers the activity
of MAT1A (Mato et al., 2002) thereby con-
tributing to the homeostasis of DNA and
histone methylation.
GSH influence on the epigenetic mech-
anisms may go beyond mere regulation of
SAM levels by the mechanism described
above. Our recent results (García-Giménez
et al., 2013b) report the implication of
GSH in the regulation of epigenetic mech-
anisms by redox phenomena. We recently
described the S-glutathionylation of his-
tone H3 as a new post-translational mod-
ification, PTM in the histone code. In
this modification, GSH binds to Cys110
in histone H3 (Histone H3 variants, H3.1,
H3.2, and H3.3) producing changes in the
stability of the nucleosomes and altering
the chromatin structure by decreasing the
proportion of α-helices. Interestingly, we
also observed how S-glutathionylation of
H3 increased in proliferating cells but not
in quiescent cells, suggesting that GSH
modifies the structure of the chromatin
during cell proliferation. The implications
of these results are relevant because the
opening of the chromatin by histone glu-
tathionylation contributes to the bind-
ing of the replication machinery to the
DNA. Furthermore, the ability of GSH
to open the chromatin may increase the
susceptibility of DNA to the attack of
DNA-interacting drugs. Our results agree
with those obtained by de Luca et al. in
which glutathionylation of H3 may facil-
itate the interaction of doxorubicin with
DNA, thereby increasing the effect of the
treatment to doxorubicin-resistant MCF7
breast cancer cells (de Luca et al., 2011).
However, the epigenetic mechanisms
described above are just two examples
of the many epigenetic events in which
GSH may be involved. For example,
oxidative stress induces the formation
of methionine sulfoxide from methion-
ine and this molecule can immediately
react with radical hydroxyl to generate
a methyl radical that non-enzymatically
and non-specifically methylates cytosine
in the DNA (Kawai et al., 2010). This
phenomenon could produce deleterious
effects in our epigenome (Lewandowska
and Bartoszek, 2011). Fortunately, a
GSH-dependent enzymatic mecha-
nism that prevents the production of
methionine sulfoxide does exist. The
GSH/glutaredoxin system can regenerate
the activated form of methionine sulfoxide
reductase, MSR, the enzyme that converts
methionine sulfoxide to methionine (Kim,
2012). Therefore, GSH/glutaredoxin/MSR
prevents the generation of the methyl rad-
ical and contributes to the regeneration of
methionine, which in turn is introduced in
the methionine cycle to recover the SAM
levels.
Furthermore, it was recently reported
that oxidative stress affects methionine
synthase (MS), an important enzyme
in the regeneration of methionine from
homocysteine (Muratore et al., 2013).
A decrease in MS activity results in ele-
vated levels of homocysteine, which is
associated with blindness, neurological
symptoms, and birth defects including
encephalopathy and megaloblastic anemia
(Outteryck et al., 2012). For this reason,
cellular redox control in which GSH, as the
main cellular antioxidant is involved, con-
fers GSH the relevant role of controlling
key enzymatic processes. These are directly
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related to the homeostasis of DNA methy-
lation to prevent extensive DNA and his-
tone methylation changes, which in turn
would produce harmful consequences.
A number of diseases have been
described in which impaired methyla-
tion and changes in GSH levels have
been reported. This is the case of several
psychiatric disorders, like schizophre-
nia (Regland et al., 1994; Yao et al.,
2006), bipolar disorder (Frey et al., 2007;
Kuratomi et al., 2008), and autism (James
et al., 2004, 2006) which underscores the
role of GSH andDNAmethylation in these
diseases.
Therefore, the evidence reported in
this manuscript indicates that pharmaco-
logical interventions designed to recover
GSH homeostasis favor the correct func-
tion of the methionine cycle (MAT1A and
MS), the replenishment of SAM, and pre-
vent the non-specific methylation reac-
tions by reducing MSR. Furthermore, as
mentioned above, oxidative stress con-
trols the activity of MS, which produces
methionine. This amino acid is then used
by the MAT1A (which is also controlled
by the GSH/GSSG ratio) to produce SAM.
This intermediate, besides participating as
a substrate for DNMTs and HMTs, is
also one of the precursors of the tran-
sulfuration pathway that finally produces
cysteine, which is used for the synthesis
of GSH.
Consequently, efforts to increase
cellular GSH concentration by direct
administration of GSH analogs have been
a challenge over recent decades (reviewed
in Wu and Batist, 2013). Some approaches
were developed for clinical application in
order to increase the stability and uptake
of GSH by cells (Sheh et al., 1990; Shibata
et al., 1995). Therefore, by controlling
the levels of both metabolites we can
counterbalance the cellular redox and
methylation status. In so doing, it was
found that the administration of drugs
(i.e., butanedisulphonate) that increase
the levels of SAM produces the recovery
of GSH levels. This strategy was proposed
as a therapeutic approach in HIV patients
with central nervous system affectation
who presented decreased concentrations
of SAM and GSH (Castagna et al., 1995).
However, the recovery of GSH concen-
tration in human tissues is difficult due
to its biochemical and pharmacokinetic
properties but different strategies are being
developed to replenish GSH levels (for a
review see Cacciatore et al., 2010). Due
to the short half-life of GSH in human
plasma and its difficulty to penetrate the
plasma membrane, it is necessary to pro-
vide a high dose to recover physiological
levels of the GSH. The use of prodrugs is
the most promising approach (Anderson
and Luo, 1998) and they present the pos-
sibility to be used as modulators of GSH
and SAM levels in this kind of diseases.
Another possible approach is the use
of co-drugs. Two different compounds are
administered simultaneously, when using
this class of chemicals. Both compounds
are linked to each other by using a cova-
lent bond that is cleavable which regen-
erates the original drug with adequate
bioavailability. Investigations in this type
of compounds have already been reported
(Ehrlich et al., 2007). In addition, as we
have described, oxidative stress produces
methionine sulfoxide, which is epigenet-
ically toxic. Therefore, the use of antiox-
idants could prevent the formation of
this oxidized amino acid. It was recently
reported that antioxidants like vitamin
C regulate epigenetic mechanisms. It has
been described how vitamin C, modulates
the activity of Tet methylcytosine dioxy-
genases, which are involved in the for-
mation of 5-hydroxymethylcytosine, thus
participating in the demethylation of DNA
(Chen et al., 2013; Minor et al., 2013).
These authors described how vitamin C
by acting as a cofactor for Tet pro-
teins enhances the 5-hidroxymethylation
of cytosine (5-hmC) at critical loci for
somatic cell reprogramming (Chen et al.,
2013; Minor et al., 2013). Thus, they
described for first time the role of ascor-
bate modulating the epigenetic control
of genome. The authors also studied the
effect of GSH as reducing agent, but they
observed that levels of 5-hmC were not
affected (Minor et al., 2013). However,
in their experiments the authors used
GSH, which do not penetrate the plasma
membrane. It would be very relevant to
reproduce their experiments by incubating
MEFs with glutathione ethyl ester, which
is able to cross the cellular membranes to
conclude if GSH can affect the levels of
5-hmC in the DNA.
The related mechanisms described in
this manuscript place the GSH and redox
control in the landscape of the epigenetic
regulation. The modulation of GSH and
SAM levels has the potential to control
oxidative stress and epigenetics. Therefore,
the design of strategies and the synthesis
of therapeutic drugs that help to reestab-
lish the levels of these key molecules are
crucial for therapeutic interventions in
epigenetic-related diseases.
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